ENLV – enlivex therapeutics ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
Enlivex Adopts Bitcoin Treasury Reserve Strategy
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Form 6-K Enlivex Therapeutics For: Nov 20
Form SC 13G Enlivex Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Form 6-K Enlivex Therapeutics For: Nov 14
Form 6-K Enlivex Therapeutics For: Nov 12
Form 6-K Enlivex Therapeutics For: Nov 08
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.